A short-acting nasal psychedelic eased hard-to-treat depression in a phase 2b trial
In a phase 2b trial published Oct. 26, 2026, in JAMA, one intranasal dose of mebufotenin cut depression scores more than a very low dose at day 29 in adults with treatment-resistant…